Recent Updates
Recently added Catalysts
NPCE Positive Sentiment Score: 75/100

NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

Key Takeaway: NeuroPace, Inc. has announced that it will report its financial results for the first quarter of 2023 on May 4, 2023, after market close. The company, based in Mountain View, California, specializes in medical devices aimed at improving the lives of individuals with epilepsy. A conference call will be held following the financial report, which can be accessed via a live and archived webcast. NeuroPace's RNS System is recognized as a groundbreaking platform for providing personalized treatments for patients with epilepsy.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is focusing on improving the lives of epilepsy patients.
  • The company is set to report financial results, indicating ongoing operations.
  • Its novel RNS System offers personalized treatment for drug-resistant epilepsy.

Full Press Release Details

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.neuropace.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When will NeuroPace release its Q1 2023 financial results?

NeuroPace will report its Q1 2023 financial results after market close on May 4, 2023.

What time is the NeuroPace conference call scheduled?

The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Where can I access the NeuroPace conference call?

You can access the webcast at www.neuropace.com on the Investors page.

What is the RNS System by NeuroPace?

The RNS System is a brain-responsive platform that delivers real-time treatment for seizures.

Who can benefit from NeuroPace's technology?

Patients with drug-resistant epilepsy and those suffering from other brain disorders may benefit.

Last updated: Apr 17, 2023